Physician Views: Orencia approved for psoriatic arthritis

Last week, the FDA approved Bristol-Myers Squibb's Orencia for the treatment of adults with psoriatic arthritis, based on data showing superior efficacy to placebo in both anti-TNF failure and anti-TNF naïve patients.

This market is becoming increasingly crowded with Eli Lilly's Taltz and Pfizer's Xeljanz – both already approved for rheumatoid arthritis – other potential future entrants. In recent months, Novartis has cited growing use of Cosentyx in the psoriatic arthritis market as a key component of the drug's growth trajectory and anecdotal evidence points to competition with Johnson & Johnson's Stelara in TNF-failure patients.

To gauge the potential impact of Orencia's approval for psoriatic arthritis in the US market, we are snap-polling a sample of US rheumatologists with the following questions…

The FDA has approved Orencia (abatacept) for the treatment of psoriatic arthritis in adult patients. Do you consider this a compelling addition to the choice of treatments available for psoriatic arthritis?


Yes – slightly compelling

Yes – moderately compelling

Yes – very compelling

Yes – extremely compelling

Orencia (abatacept) is already approved for the treatment of adult rheumatoid arthritis and juvenile idiopathic arthritis. Will lack of a psoriasis indication on its label limit utilisation as a treatment for psoriatic arthritis?


Yes – slightly

Yes – moderately

Yes – significantly

Yes – very significantly

Approximately what percentage of psoriatic arthritis patients would you expect to treat with Orencia (abatacept)?


What brand(s) would you expect to use Orencia (abatacept) most frequently instead of?



Stelera (ustekinumab)

Cosentyx (secukinumab)

Otezla (aprelimast)

Currently, which of the following treatment options are you most increasing your use of in patients who have progressed from therapy with one or more anti-TNF?

Stelera (ustekinumab)

Cosentyx (secukinumab)

Otezla (aprelimast)

Other (please state)

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.